Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 18, 2026 08:20 ET | Source: Moleculin Biotech, Inc.

Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30)

Preliminary blinded CR rate showed 67% improvement over historical cytarabine response Roughly 35% of the subjects treated to date represent ventoclax regimen failuresFirst 45 subjects treated on...